Michael Jensen

Michael Jensen

Founder, Chief Scientific Officer at BrainChild Bio, Inc.
Greater Seattle Area

Michael Jensen is Chief Scientific Officer at BrainChild Bio, Inc. and Co-Founder at Umoja Biopharma. He was Chief Therapeutics Officer at Seattle Children's and Executive Director at CureWorks. He was Founding Director at Ben Towne Center for Childhood Cancer Research, SCRI, and Joint Member at FHCRC. He was Founder and SAB Member at Juno Therapeutics. He was also Professor at UWSOM and Professor at Beckman Research Institute at City of Hope.

BrainChild Bio Raises $116M Series A on Sept. 8 to Fund Phase 2 B7-H3 CAR T Trial for DIPG

BrainChild Bio raised $116 million in a Series A on Sept. 8 to fund a registrational Phase 2 trial of BCB-276, a B7-H3 CAR T therapy delivered directly into cerebrospinal fluid for DIPG, and to advance a triple-antigen glioblastoma program. The Seattle Children’s spinout aims to bypass the blood-brain barrier with intrathecal delivery after promising early survival signals.

BrainChild Bio raises $116M Series A to fund Phase 2 CAR T trial for childhood DIPG

Seattle startup BrainChild Bio raised $116 million in Series A funding to advance a CAR T cell therapy for diffuse intrinsic pontine glioma (DIPG) and to support development of additional pediatric and adult brain tumor CAR T programs. The financing will fund a pivotal ILLUMINATE Phase 2 registration-stage trial and was led by an undisclosed private family fund and foundation, with participation from Seattle Children’s and WRF Capital.

See all 16 stories, episodes and videos about Michael Jensen.

Organizations

See all 9

Education

  • University of Pennsylvania Doctor of Medicine (M.D.) · 1986–1990
  • Tufts University Bachelor's degree, Biology/Biological Sciences, General · 1982–1986
  • Saint Mark's School, Southboro, MA. High School · 1978–1982

Online